[Utility of rabeprazole as a diagnostic test in non-erosive gastroesophageal reflux disease]

Rev Gastroenterol Mex. 2005 Jul-Sep;70(3):276-83.
[Article in Spanish]

Abstract

Background: Proton pump inhibitor test (PPIt) has been shown adequate diagnostic usefulness and cost-effectiveness in the evaluation of patients with gastroesophageal reflux disease (GERD). However, comparative studies of PPIt with 24 hr esophageal pH-metry (24-pH) in non erosive GERD (NERD) are scarce and the utility of rabeprazole as a PPIt has not been evaluated.

Objective: To investigate the diagnostic utility of rabeprazole test in patients with NERD.

Material and methods: An open label trial was performed, and NERD patients with heartburn at least 3 times per week were included. Symptomatic evaluation before, during and after rabeprazole 20 mg bid for 7 days was performed. All patients underwent 24-pH before treatment with rabeprazole. Patients were classified in three groups: 1) abnormal pH, 2) normal pH and symptom index (SI) positive, and 3) normal pH and SI negative. A positive rabrepazole test was considered when symptoms improvement was higher than 50% at the end of the test. Sensitivity, specificity, negative predictive value, positive predictive value and positive likelihood ratio were calculated considering the 24-pH as gold standard.

Results: Sixty four patients, 47 (72%) female were studied. Forty four percent of the patients had normal pH, 29% with SI positive and 71% with SI negative. Sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio were 82%, 47%, 78%, 52% and 1.406 respectively. No adverse events were reported.

Conclusion: PPI test with rabeprazole 20 mg bid for 7 days is a simple and useful test in the diagnostic approach of patients with NERD.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles*
  • Adolescent
  • Adult
  • Female
  • Gastroesophageal Reflux / diagnosis*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Proton-Translocating ATPases / antagonists & inhibitors*
  • Rabeprazole

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Rabeprazole
  • Proton-Translocating ATPases